Yanhong Chen

Yanhong Chen


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YCYanhong Chen
Yanhong Chen
HBHector Barajas-Martinez
Hector Barajas-Martinez
DZDongxiao Zhu
Dongxiao Zhu
XWXihui Wang
Xihui Wang
CCChonghao Chen
Chonghao Chen
DHDan Hu
Dan Hu
Hypertrophic cardiomyopathy (HCM) patients with early repolarization (ER) pattern are at higher risk of ventricular arrhythmia, yet the genetic background of this situation has not been well investigated. Here we report novel trigenic mutations detected in a Chinese family of obstructive HCM with ER and short QT syndrome (SQTS). Proband and family members underwent detailed medical assessments. DNAs were extracted from peripheral blood leukocytes for genetic screening with next generation method. The functional characterization of the mutation was conducted in TSA201 cells with patch-clamp experiment. The proband was a 52-year-old male who had a ER pattern ECG in inferioral-lateral leads with atrioventricular block and QTc of 356 ms. He also suffered from severe left ventricular hypertrophy and dysfunction. Targeted sequencing revealed trigenic mutations: c.700G>A/p.E234K in DES, c.2966G>A/p.R989H in MYPN, and c.5918G>C/p.R1973P in CACNA1C. All mutations were also detected in his daughter with ER and mild myocardium hypertrophy. The CACNA1C-R1973P mutation caused significant reduction (68.4%) of ICa compared to CACNA1C-WT (n = 14 and 14, P < 0.05). The computer modeling showed that all 3 mutations were highly disease-causing. The proband received the CRT-D (cardiac resynchronizing therapy) implantation, which lowered the left ventricular outflow tract gradient (LVOTG, 124 mmHg pre vs. 27 mmHg post) and restored the LV function (LVEF 40% pre vs. 63% post). The study reveals a novel CACNA1C mutation underlying the unique ER pattern ECGs with SQTS. It also shows the rare trigenic mutations are the pathogenic substrates for the complicated clinical manifestation in HCM patients.

19 May 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ZHZhengping Huang
Zhengping Huang
SLShu-Fen Liu
Shu-Fen Liu
JZJian-Long Zhuang
Jian-Long Zhuang
LLLin-Yi Li
Lin-Yi Li
MLMi-Mi Li
Mi-Mi Li
CCChunnuan Chen
Chunnuan Chen

26 June 2011 in Science China Life Sciences
Verified
Journal Article
Open access
PDF file
SZShu Jeffrey Zhu
Shu Jeffrey Zhu
XGXinna Ge
Xinna Ge
XGXiaoWen Gong
XiaoWen Gong
XGXin Guo
Xin Guo
YCYanhong Chen
Yanhong Chen
Hanchun YangHanchun Yang
Hanchun Yang
Encephalomyocarditis virus (EMCV) infection leads to many diseases including encephalitis, myocarditis and diabetes in its natural host, the mouse. In this study, we generated four cDNA clones with a point mutation at position 100 of VP1. The amino acids isoleucine, alanine, serine and proline were substituted with threonine in the four different clones of EMCV strain BJC3 by site-specific mutagenesis, and viable viruses were rescued. Although all mutants and wild-type viruses display different plaque morphologies, they replicate comparably in BHK-21 cells. The pathogenicity of the mutated viruses was systematically analyzed to investigate the importance of this amino acid in the viral pathogenicity and disease phenotype of EMCV infection in mice. The results showed that the isoleucine- (T1100I) and proline-mutated viruses (T1100P) exhibited a reduced mortality, lower cerebral virus loads and alleviated brain damage while the viruses with serine (T1100S) and alanine (T1100A) substitutions displayed similar properties as the wild-type virus. These findings indicate that the amino acid at position 100 of VP1 is important for EMCV in vivo infection, and its mutation alters the pathogenicity of viral infection in mice.

18 July 2019 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
YCYuyi Chen
Yuyi Chen
YZYong-Hua Zhang
Yong-Hua Zhang
XCXin Chen
Xin Chen
WHWei-Ping Huang
Wei-Ping Huang
BXBei Xu
Bei Xu
YCYanhong Chen
Yanhong Chen

5 March 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
YCYuyi Chen
Yuyi Chen
YZYonghua Zhang
Yonghua Zhang
LQLulu Qu
Lulu Qu
WHWeiping Huang
Weiping Huang
XSXi Su
Xi Su
YCYanhong Chen
Yanhong Chen

17 January 2023 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
CCChunyu Chen
Chunyu Chen
YCYuyi Chen
Yuyi Chen
LQLulu Qu
Lulu Qu
XSXi Su
Xi Su
YCYanhong Chen
Yanhong Chen
Introduction: Left atrial appendage closure (LAAC) is a novel treatment for stroke prevention in high-risk patients with non-valvular atrial fibrillation (NVAF). However, the long-term outcomes after LAAC in Chinese NVAF patients are still lacking. Methods: This was a single-center, bidirectional, nonrandomized registered study. Patients who underwent LAAC implantation from May 2014 to April 2021 in a large Chinese center were enrolled. The primary endpoint was combined all-cause death and stroke. Results: From May 2014 to April 2021, a total of 673 NVAF patients were enrolled. The overall successful implantation rate was 97.62% (657 of 673). The rate of perioperative adverse events was 1.19% (8 of 673), including 3 cardiac tamponades, 2 ischemic strokes, one device-related thrombus (DRT) and 2 device dislocations. 604 (92.24%) patients completed the follow-up, the median follow-up period was 36.9 months (IQR 24.8–56.5 months). 16 stroke events occurred in 15 patients (one patient suffered from both hemorrhagic and ischemic strokes). 13 patients (2.15%) had ischemic stroke, and the fatal rate was 0.33% (2 of 604). 3 patients (0.15%) suffered from hemorrhagic stroke, and the fatal rate was 0.17% (1 of 604). The overall stroke rate was 0.74% per-year. The combined death and stroke rate was 1.93% per-year. In the multivariate Cox regression analysis, age ≥ 75 (hazard ratio 2.264, 95% CI 1.074–4.772, P = 0.032) and ventricular cardiomyopathy (hazard ratio 2.738, 95% CI 1.060–7.071, P = 0.037) were independent predictors of combined mortality and stroke. Conclusion: The overall successful implantation rate of LAAC was 97.62% and the rate of perioperative adverse events was 1.19% in this study, and the stroke rate was 0.74% per year during the long-term follow-up. Age ≥ 75 years and ventricular cardiomyopathy were independent predictors of the primary endpoint. Trial registration This study was retrospectively registered.